StudyFinder
Search Results
641 Study Matches
A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma
Stevens, Sarah - sstevens23@vcu.edu
Poklepovic, Andrew, S
NCT04833582
HM20023239
drug: Zn-c3,
drug: Gemcitabine
Bones and Joints
Unpacking Multilevel Drivers of Cardiotoxicity Disparities in Breast Cancer Survivors
Sutton, Arnethea - abrahamal@vcu.edu
Sheppard, Vanessa, B.
16953
HM20019941
Breast
Cognitive Support Technology for Postsecondary Students with Traumatic Brain Injuries
Getzel, Elizabeth, E - lgetzel@vcu.edu
Getzel, Elizabeth, E
17135
HM20019040
External Causes of Injury and Poisoning (800-999)
Prognostic Gene Expression Profiling and Adjuv Therapy in Stage IIB-C & IIIA-B Cutaneous Melanoma
Gnanasigamani Manogaram, Merlin Margaret - gnanasigamam@vcu.edu
Poklepovic, Andrew, S
17390
HM20021149
Melanoma, skin
Feasibility, Acceptability, and Preliminary Effectiveness of the ICAN QUIT Tobacco Program at VCUH
Hunley, Rachel - rachel.hunley@vcuhealth.org
Hayes, Rashelle
17440
HM20020118
Any Site
Assessing Electronic Cigarette Nicotine Flux (Project 2 Flux Study)
ctrrecruit@vcu.edu
Breland, Alison
19170
HM20018580
Any Site
Longitudinal Survey and Behavior Assessment of Experienced E-cigarette Users (P4 @ VCU)
ctrrecruit@vcu.edu
Breland, Alison
19168
HM20018209
Any Site
Salad Bars in the National School Lunch Program
ctrrecruit@vcu.edu
Bean, Melanie, K.
19167
HM20012226
Any Site
Predicting Effects of Tobacco Product Flavor Regs Among Black/African American Menthol Smokers
ctrrecruit@vcu.edu
Cobb, Caroline
19166
HM20022619
Any Site
Effects of E-Cigarette Nicotine Delivery on Abuse Liability in Smokers
ctrrecruit@vcu.edu
Cobb, Caroline
19165
HM20018290
Any Site
Noninvasive Assessment of Esophageal Varices in Patients with Unresectable Hepatocellular Carcinoma
ctrrecruit@vcu.edu
Wedd, Joel
19108
HM20023235
Pt QoL & Social Support after Cytoreductive Surgery & Hyperthermic Intraperitoneal Chemo
Freudenberger, Devon - devon.freudenberger@vcuhealth.org
Trevino, Jose
19045
HM20023396
Soft Tissue
Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis (RheSolve)
Brett Bannan - brett@galatherapeutics.com
Shepherd, Ray, Wes
NCT04677465
HM20022653
Inclusion Criteria:
• Patient is at least 35 years of age.
• Patient has chronic bronchitis, defined as productive cough for three months in each of two successive years, whereas other causes of productive cough have been ruled out.
• Patient has a CAT score ≥ 10.
• Patient has an SGRQ score ≥ 25.
• Patient's responses to the first two questions of the CAT instrument sum to ≥ 7 points or the sum is 6 points and the patient's total CAT score is > 20 points.
• Patient has FEV1/FVC < 0.70.
• Patient has a pre-procedure post-bronchodilator FEV1 percent predicted of ≥ 30%.
• Patient is receiving guideline directed pharmacotherapy which includes one or more long acting bronchodilator (LAMA, LABA) with or without an inhaled corticosteroid for at least 8 weeks prior to randomization, unless the patient has attempted such therapy within the past 1 year without significant clinical response or had an adverse reaction.
• Patient has a cigarette smoking history of at least ten pack years.
• In the opinion of the Primary investigator, patient is able to undergo 2 bronchoscopies under general anesthesia and is able to adhere to the study follow-up schedule
Exclusion Criteria:
• Patient has known unresolved lower respiratory tract infection (e.g., pneumonia, mycobacterium avium-intracellulare infection (MAI), fungus, tuberculosis).
• Patient has a steroid-dependent condition requiring >10 mg of oral corticosteroid per day.
• Patient has any implantable electronic device (e.g., pacemaker, cardioverter defibrillator) that cannot be turned off during the procedure.
• Patient has a history of ventricular tachy-arrhythmia or clinically significant atrial tachyarrhythmia within the past two years, unless the arrhythmia has been treated and/or patient is in regular rhythm during the screening phase.
• Patient has unresolved lung cancer.
• Patient has a pulmonary nodule or cavity that in the judgement of the Primary investigator may require intervention during the course of the study.
• Patient had prior lung surgery, such as lung transplant, LVRS, lobectomy, lung implant/prosthesis, metal airway stent, valves, coils or bullectomy. Prior pneumothorax without lung resection, pleural procedures without surgery, or segmentectomy are acceptable.
• Patient has emphysema of greater than or equal to 25% as quantified on baseline HRCT scan (low attenuation area less than -950HU) as determined by the CT Core Lab.
• Patient has asthma based on Global Initiative for Asthma (GINA) criteria.
• Patient has clinically significant bronchiectasis influencing the patient's clinical symptoms of cough and phlegm.
• Patient has actively smoked (including tobacco, marijuana, e-cigarettes, vaping, etc.) within the last 6 months.
• Patient is unable to walk over 225 meters in 6 minutes.
• Patient has a serious medical condition that, in the Primary investigator's opinion, could compromise patient safety or confound the interpretation of the patient's response to therapy (e.g., congestive heart failure, cardiomyopathy, or myocardial infarction in the past year, renal failure, liver disease cerebrovascular accident within the past 6 months, uncontrolled diabetes (HbA1c >8%), uncontrolled hypertension (diastolic BP >100mmHg) or autoimmune disease requiring treatment with immunosuppressant medications or a disease requiring chemotherapy).
• Patient has uncontrolled GERD.
• Patient has known severe pulmonary hypertension.
• Patient has a known sensitivity to medication required to perform bronchoscopy (i.e., lidocaine, atropine, benzodiazepines).
• Patient is pregnant, nursing, or planning to get pregnant during study duration.
• Patient is currently participating in another clinical study involving an investigational product
Device: RheOx Bronchial Rheoplasty, Device: Sham Procedure
Chronic Bronchitis
COPD
Role of GABA in Motor Symptoms and Neurophysiological Abnormalities in Dystonia
Crump, Elizabeth - crumpeg@vcu.edu
Berman, Brian
18815
HM20021040
Diseases of Nervous System and Sense Organs (320-389)
Cancer Prevention for Virginia Firefighters
ctrrecruit@vcu.edu
Burch, James
18656
HM20022904
Any Site
ECMT? Consortium (ECMT2)
Ghobrial, Silvia - ghobrials@vcu.edu
Randall, Leslie
18243
HM20022876
Other Female Genital, Corpus Uteri
UPBEAT-DIET (UPBEAT_Die)
Bellissimo, Moriah - Moriah.BellissimoMyers@vcuhealth.org
Hundley, W. Gregory
18021
HM20021545
Breast
Women's Treatment Experiences Study (WTES)
ctrrecruit@vcu.edu
Sheppard, Vanessa, B.
17999
HM20020923
Breast
Validation of the BLESS Models for Predicting Survival in Breast or Lung Cancer
Shojaee, Samira - samira.shojaee@vcuhealth.org
Shojaee, Samira
17961
HM20021607
Any Site
Role of Circadian Factors in Inflammation and Colorectal Adenoma Risk
Shetty, Shreya - shettysa@vcu.edu
Burch, James
17947
HM20021857
Rectum, Colon
Longitudinal Cohort Registry of Cancer Survivors
Hong, Susan - susan.hong@vcuhealth.org
Hong, Susan
17880
HM20021510
Anus, Any Site, Bones and Joints, Breast, Brain and Nervous System, Other Hematopoietic, Other Female Genital, Other Endocrine System, Other Digestive Organ, Non-Hodgkin's Lymphoma, Myeloid and Monocytic Leukemia, Mycosis Fungoides, Multiple Myeloma, Melanoma, skin, Lymphoid Leukemia, Lung, Liver, Lip, Oral Cavity and Pharynx, Leukemia, other, Leukemia, Not Otherwise Specified, Larynx, Kidney, Kaposi's sarcoma, Ill-Defined Sites, Hodgkin's Lymphoma, Eye and Orbit, Esophagus, Corpus Uteri, Colon, Cervix, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Urinary, Urinary Bladder, Thyroid, Stomach, Soft Tissue, Small Intestine, Rectum, Prostate, Pancreas, Ovary, Other Skin
Multiplex Analysis of Venetoclax Sensitivity in Patients Diagnosed with AML or CLL
Lantis, Kristin - kllantis@vcu.edu
Grant, Steven
17581
HM20020962
Myeloid and Monocytic Leukemia, Lymphoid Leukemia
The Impact of Sarcopenia in Patients with Cirrhosis
Evans, Marie-Claire - marieclaire.evans@vcuhealth.org
Siddiqui, Mohammad, S
18741
HM20019626
Diseases of Digestive System (520-579)
Impacts of COVID-19 on Cigarette Smoking Behaviors
ctrrecruit@vcu.edu
Breland, Alison
19171
HM20019258
Any Site
Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT
Suna Chung, MPH - schung60@jhu.edu
Kates, Stephen, L
NCT04678154
HM20022236
Inclusion Criteria:
• Injury meeting at least one of the following criteria: * Gustilo type III tibia (OTA 41 plateau, OTA 42 shaft and OTA 43 pilon) requiring a second procedure for final debridement and definitive coverage / closure following the index stabilization * Gustilo type IIIB ankle fractures (OTA 44) * Gustilo type IIIB calcaneus fractures (OTA 82) * Gustilo type IIIB talus fractures (OTA 81) * Traumatic "zone-of-injury" trans-tibial amputations requiring DPC, and/or flap coverage
• Ages 18 - 64 years inclusive
• Patients may have risk factors for infection including diabetes, immunosuppression from steroids or other medications, HIV, or other infections.
• Patients may have a traumatic brain injury.
• Patients may have other fractures including spine, upper extremity fractures, contralateral lower extremity injuries, ipsilateral pelvis, hip, femur or foot injuries.
• Patients may be treated initially at an outside institution prior to transfer to the study institution, as long as the definitive wound closure or coverage was not performed prior to entrance into the study.
• Patients with bilateral injuries that meet inclusion criteria may be included, but only the limb rated as "more severe" by the treating surgeon will be enrolled in the study.
• Patients may have co-existing non-tibial or hindfoot infection, with or without antibiotic treatment.
• Patients may be definitively stabilized using any method (nail, plate, ex fix or cast).
• Patients may have a fasciotomy.
Exclusion Criteria:
• Patient in current therapy for a wound, implant or fracture site infection related to the study site.
• Patient likely to have difficulty maintaining follow-up, including: * Diagnosis of a severe psychiatric condition * Intellectually challenged without adequate family support * Resides outside of the hospital's catchment area * Planning to follow-up at another medical center * Being a prisoner * Not having a means of contact (address, cell phone, home phone, e-mail)
DRUG: Standard of care, DRUG: Vancomycin and Tobramycin
Post Operative Surgical Site Infection
Surgical site infection risk prevention, Bacterial species type and antibacterial sensitivities
Observational - Characteristics, Treatment, Outcomes -Severe Asthma in the US (CHRONICLE)
Toft, Robin - robin.toft@vcuhealth.org
Mohan, Arjun
NCT03373045
HM20022693
Modality: No vcuhs billing
Diseases of Respiratory System (460-519)
Efficacy/Safety SPR001 (Tildacerfont) Reducing Supraphysiologic Glucocorticoid Use in Adults w CAH
Memoli, Erica, H - erica.memoli@vcuhealth.org
Gupta, Anshu
NCT04544410
HM20019420
drug: Spr001 (tildacerfont)
Endocrine, Nutritional, Metabolic Diseases, Immunity Disorders (240-279)
Efficacy/Safety of SPR001 (Tildacerfont) in Adults with Classic Congenital Adrenal Hyperplasia
Memoli, Erica, H - erica.memoli@vcuhealth.org
Gupta, Anshu
NCT04457336
HM20019413
drug: Spr001 (tildacerfont)
Endocrine, Nutritional, Metabolic Diseases, Immunity Disorders (240-279)
Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE
Coleman, PARIS - paris.coleman@vcuhealth.org
Smallfield, George, B
NCT04293458
HM20018839
Diseases of Digestive System (520-579)